Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection
Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis
Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company
Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination
Petra Acquisition, Inc. Announces Special Meeting of Stockholders to Approve Business Combination with Revelation Biosciences, Inc.
Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza
Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board
Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion
Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID
Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify a Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)
Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion
Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx-99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections
Revelation Biosciences a Life Sci. Co. Developing Therapeutics & Diag. for Respiratory Viral Infections Including COVID-19 to Become Publicly Traded through a Merger with Petra Acquisition Inc
Revelation Biosciences Inc. to Present at 2021 BIO Digital Conference
Revelation Biosciences Inc. Announces Results of Phase 1 Clinical Study of REVTx‑99, an Experimental Therapy for the Prevention of Respiratory Viral Infection
Revelation Biosciences Inc. to Present at BIO CEO & Investor Digital Conference
Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase 1 Clinical Study of REVTx‑99
Revelation Biosciences Inc. Announces Closing of $4.4 Million in Series A-1 Financing
Curt LaBelle, M.D. Appointed to Revelation Biosciences, Inc. Board of Directors
Revelation Biosciences Inc. Announces $9.1 Million Common Stock and Series A Financing
